Quantum BioPharma announced reaching the halfway point in its collaborative study with Massachusetts General Hospital, using a novel PET imaging technique to track demyelination in multiple sclerosis (MS) patients. Early imaging results show strong detection of MS lesions, potentially improving how disease progression and treatment response are measured. This advancement supports the development of Quantum's Lucid-MS, a drug candidate aimed at protecting and restoring myelin, with a Phase 2 trial underway following FDA IND submission. The new imaging method could accelerate MS therapy development by providing precise, real-time insights into myelin health.
ISS A/S announced that it now holds 2,251,359 treasury shares, which is less than 5% of its total share capital and voting rights. This reduction follows a share capital reduction approved at the company's Annual General Meeting on April 16, 2026, wh...
ISS A/S has completed its share capital reduction by cancelling treasury shares, reducing the nominal share capital from DKK 174.2 million to DKK 160 million. This follows approval at the annual general meeting and registration with the Danish Busine...
During week 20 of 2026 (May 11-15), Sampo Oyj repurchased a total of 1,730,961 of its A-shares across multiple marketplaces at an average price of about €8.92 per share. This buyback is part of a €350 million share repurchase program authorized by th...
Anthony Scaramucci criticized the US decision to grant China permanent trade relations and WTO membership, saying it allowed China to protect its economy while exporting freely to the US. He argued that China used this advantage to take US technology...
Aon plc announced the launch of Aon Digital Placement Exchange (Aon DPX), a new digital platform aimed at modernizing how brokers access capital and syndicate risk, specifically for Follow Line business in the London Market. The platform uses structu...
